CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Savella (milnacipran) prior authorization for fibromyalgia

Defines step therapy and prior authorization criteria for coverage of Savella (milnacipran) for treatment of fibromyalgia under the payer's pharmacy benefit; affects prescribers and pharmacists managing outpatient prescriptions.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicySavella (milnacipran) prior authorization for fibromyalgia

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document patient is ≥18 and has trialed duloxetine or has intolerance/contraindication, or evidence of a prior ≥30‑day pregabalin or duloxetine fill within 120 days.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

18+min patient age

30 daysprior fill min

120 dayslook‑back

6 moinitial approval

36 mocontinuation approval

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage criteria for Savella (milnacipran)

Coverage criteria (initial and continuation)

Covered with prior authorization when ALL/OR logic below is satisfied as written in the source document.

Primary requirements

Initial therapy: duloxetine step: Patient has experienced an inadequate treatment response to duloxetine
Chunk 3
Exceptions to duloxetine step: Patient has experienced an intolerance to duloxetine OR has a contraindication that would prohibit a trial of duloxetine
Chunk 4
Prior-fill pathway: Patient has filled a ≥30 day supply of immediate‑release pregabalin or duloxetine within the past 120 days under a CVS Caremark‑administered prescription benefit (triggers PA processing)≥30 days within 120 days
Chunk 1
Continuation pathway: Request is for continuation of therapy
Chunk 4

Continuation requirement: For continuation of therapy, patient has achieved or maintained a positive clinical response to the requested drug (e.g., improvement in pain)

Chunk 5

Savella (milnacipran) is not approved for use in pediatric patients.

What providers must do

Prior Authorization

Prior Authorization Required

Prior authorization is required for Savella when prescribed for fibromyalgia. Providers must submit a PA and include required documentation (see below). Savella is not approved for pediatric patients.

PA required for Savella (fibromyalgia)
Patient must be ≥ 18 years of age
Not approved for pediatric use

Step Therapy

Step Therapy Requirement

Step therapy applies: a trial of duloxetine is required prior to approval unless an approved exception applies.

Required trial: duloxetine (document inadequate response, intolerance, or contraindication)
Allowed exceptions: inadequate response to duloxetine, documented intolerance, or contraindication that prohibits duloxetine trial
Continuation of therapy requests do not require an additional duloxetine trial if prior authorization criteria were previously met

Documentation Required

Required Documentation

Document the clinical information needed to process the PA. Include diagnosis, age, prior therapy history, and whether the request is for initial or continuation therapy.

Diagnosis of fibromyalgia
Patient age (must be ≥ 18 years)
For initial therapy: documentation of trial and inadequate response to duloxetine OR documented intolerance/contraindication to duloxetine
For continuation therapy: documentation of prior PA approval or evidence of maintained clinical benefit (e.g., improvement in pain)
Medication fill history if applicable (e.g., prior pregabalin or duloxetine fills under benefit)

Denial Risk

Denial Triggers

Requests may be denied if the indication is not fibromyalgia, required duloxetine trial documentation is missing, the patient is under 18, or PA/continuation criteria are not met.

Non-fibromyalgia indications are not covered
Missing documentation of required duloxetine trial, intolerance, or contraindication may lead to denial
Pediatric use (patient < 18 years) will be denied as Savella is not approved for pediatric patients
Requests that do not demonstrate initial or continued clinical benefit may be denied

Background and clinical context

Savella (milnacipran) is FDA‑approved for the management of fibromyalgia in adults; it is not approved for pediatric patients. The payer’s policy references the product labeling and applies prior authorization requirements for Savella when used to treat fibromyalgia under the pharmacy benefit.

Per the policy, prior authorization is required for coverage of Savella for fibromyalgia and coverage is granted only when the documented criteria are met, including that the patient is 18 years of age or older and that one of the step‑therapy or prior‑fill pathways applies (see coverage criteria).

Duration of approval is specified in the policy: initial approval: 6 months; continuation approval: 36 months.